Only direct cytotoxic targets are shown
| Gene | NCT ID | Antigen/Ligand | Binding Type | Drug Name | Drug NCI Concept | Drug Category | Drug Class | Drug Description | Drug Mechanism of Action | Target Cytotoxicity Mechanism | Disease | Disease Type | Tissue | OncoTree Main Type | OncoTree Name | Annotation Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | NCT06639191 | CD44v6 (CD44 variant 6) | antigen recognition | AKIR001 | RADIOIMMUNOCONJUGATE | Conjugate | CD44v6-targeting monoclonal antibody used as the targeting moiety for radioimmunotherapy; binds the CD44v6 isoform on tumor cells to deliver the attached radionuclide. | A CD44v6-targeting monoclonal antibody labeled with lutetium-177 that binds CD44v6 on tumor cells and delivers localized beta radiation, inducing DNA damage (including double-strand breaks) and tumor cell death, with a cross-fire effect to nearby CD44v6-positive cells. | A Lu-177–labeled anti-CD44v6 antibody binds CD44v6 and delivers beta radiation to the bound cell, causing DNA double-strand breaks and cell death; cross-fire can also kill nearby cells. | Non-small Cell Lung Cancer Stage IV | CANCER | Lung | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | ai | |
| CD44 | NCT06639191 | CD44 variant 6 (CD44v6) | antigen recognition | Lutetium-177 | RADIOIMMUNOCONJUGATE | Conjugate | Beta-emitting therapeutic radionuclide conjugated to AKIR001 to deliver localized ionizing radiation, causing DNA damage and tumor cell death with potential cross-fire effects. | Lutetium-177 is a beta-emitting radionuclide linked to the CD44v6-targeting monoclonal antibody AKIR001. Upon binding CD44v6 on tumor cells, it delivers localized ionizing radiation that induces DNA double-strand breaks and tumor cell death, with cross-fire effects on neighboring tumor cells. | CD44v6-binding antibody delivers 177Lu beta radiation to target cells, inducing DNA double‑strand breaks and tumor cell death (with cross‑fire to nearby cells). | Non-small Cell Lung Cancer Stage IV | CANCER | Lung | Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | ai | |
| MS4A1 | NCT05533125 | CD20 | antigen recognition | Rituximab | C1702 | CYTOTOXIC ANTIBODY | Inhibitor | Chimeric anti-CD20 monoclonal antibody that depletes circulating CD20+ B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, aiming to reduce glucocorticoid exposure and achieve steroid-free remission in polymyalgia rheumatica. | Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes CD20+ B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby suppressing B cell–mediated immune activation and inflammation. | Anti-CD20 antibody binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP (NK cells/macrophages), and can induce apoptosis, leading to lysis/depletion of CD20+ cells. | Polymyalgia Rheumatica | NON-CANCER | Other | ai | ||
| CD19 | NCT05809284 | CD19 | antigen recognition | Tisagenlecleucel (Kymriah) | CAR T | Cellular Therapy | An autologous, gene‑modified cellular immunotherapy consisting of CD19‑directed CAR T cells that incorporate an anti‑CD19 scFv with 4‑1BB costimulatory and CD3ζ signaling domains. Engagement of CD19 on B cells triggers T‑cell activation, proliferation, and cytotoxic killing of CD19+ leukemic blasts; the 4‑1BB domain supports expansion and persistence. | Autologous CD19-directed CAR T cells bearing an anti-CD19 scFv with 4-1BB costimulatory and CD3ζ signaling domains; engagement of CD19 on B cells activates the CAR T cells, driving proliferation and cytotoxic killing of CD19+ malignant cells, with 4-1BB supporting expansion and persistence. | CD19-directed CAR T cells recognize CD19 on target cells and kill them via T-cell effector mechanisms (perforin/granzyme-mediated lysis and death-receptor apoptosis). | Acute Lymphoblastic Leukemia, in Relapse | CANCER | Lymphoid | B-Lymphoblastic Leukemia/Lymphoma | B-Lymphoblastic Leukemia/Lymphoma, NOS | ai | |
| CD276 | NCT06221553 | B7-H3 (CD276) | antigen recognition | Autologous B7-H3 (CD276)-specific CAR T cells with IL-7 receptor alpha signaling domain | CAR T | Cellular Therapy | Autologous T lymphocytes genetically engineered via lentiviral transduction to express a B7-H3–targeted chimeric antigen receptor incorporating an IL-7Rα intracellular signaling domain to enhance persistence and proliferation; administered intraventricularly via CNS catheter. | Autologous T cells are engineered to express a chimeric antigen receptor targeting B7-H3 (CD276). CAR engagement of B7-H3 on tumor cells triggers MHC-independent T-cell activation via CD3ζ signaling, inducing cytotoxic killing and cytokine release. An incorporated IL-7 receptor alpha intracellular signaling domain augments IL-7/JAK-STAT5 survival and proliferative signals to enhance CAR T-cell persistence and expansion, supporting activity in the CNS when delivered intraventricularly. | B7-H3–binding CAR activates T cells (via CD3z and IL-7Ralpha signaling), triggering MHC-independent cytolysis of B7-H3+ cells through perforin/granzyme release and death-receptor pathways. | Diffuse Intrinsic Pontine Glioma | CANCER | CNS/Brain | Diffuse Glioma | Diffuse Midline Glioma, H3 K27-Altered | ai |